PolarityTE, Inc. (PTE), a developer of regenerative tissue products and biomaterials, said on Monday that it has filed its complete response to the U.S. Food and Drug Administration's or FDA's clinical hold correspondence for its Investigational New Drug or IND application for SkinTE with a proposed indication for chronic cutaneous ulcers.
"As previously disclosed, the primary hold issues are certain Chemistry, Manufacturing, and Control (CMC) items, including the assay to demonstrate the potency of SkinTE," the company said in a statement. PolarityTE's complete response to the hold issues was submitted on December 17.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.